ICU Medical, Inc. (ICUI)
NASDAQ: ICUI · Real-Time Price · USD
131.59
+2.49 (1.92%)
Sep 18, 2025, 11:32 AM EDT - Market open
ICU Medical Stock Forecast
Stock Price Forecast
The 5 analysts that cover ICU Medical stock have a consensus rating of "Buy" and an average price target of $186.6, which forecasts a 41.81% increase in the stock price over the next year. The lowest target is $153 and the highest is $209.
Price Target: $186.6 (+41.81%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ICU Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $145 → $153 | Buy | Maintains | $145 → $153 | +16.27% | Sep 10, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $145 | Buy | Initiates | $145 | +10.19% | Aug 15, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $187 → $180 | Strong Buy | Maintains | $187 → $180 | +36.79% | Aug 8, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $197 → $187 | Strong Buy | Maintains | $197 → $187 | +42.11% | May 9, 2025 |
| Keybanc | Keybanc | Buy Maintains $209 → $191 | Buy | Maintains | $209 → $191 | +45.15% | Apr 21, 2025 |
Financial Forecast
Revenue This Year
2.24B
from 2.38B
Decreased by -6.13%
Revenue Next Year
2.21B
from 2.24B
Decreased by -1.30%
EPS This Year
7.13
from -4.83
EPS Next Year
8.25
from 7.13
Increased by 15.70%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.3B | 2.4B | |||
| Avg | 2.2B | 2.2B | |||
| Low | 2.1B | 2.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.4% | 6.6% | |||
| Avg | -6.1% | -1.3% | |||
| Low | -11.0% | -7.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.38 | 9.00 | |||
| Avg | 7.13 | 8.25 | |||
| Low | 6.72 | 7.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 26.2% | |||
| Avg | - | 15.7% | |||
| Low | - | 5.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.